课题基金 / 基金详情

Targeting RHNO1 in Ovarian Cancer

Targeting RHNO1 in Ovarian Cancer
靶向 RHNO1 治疗卵巢癌
批准号:
10648755
负责人:
ADAM R. KARPF
金额:
$17.94万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-04-01 至 2025-03-31
关键词:
AblationAccountingAddressApoptosisAscitesBindingBiochemical PathwayBiological AssayBiological MarkersCHEK1 geneCancer PatientCancer cell lineCarboplatinCell LineCell SurvivalCellsCessation of lifeChemoresistanceChemotherapy-Oncologic ProcedureClinicalClustered Regularly Interspaced Short Palindromic RepeatsComplexDNA DamageDNA RepairDNA biosynthesisDevelopmentDiagnosisDiseaseDisease ResistanceDrug DesignDrug TargetingEpithelial CellsExhibitsFluorescence PolarizationFutureGoalsGreater sac of peritoneumGrowthHumanHus1 proteinImageImmunohistochemistryImplantInvestigationKineticsKnock-outLuciferasesMalignant Female Reproductive System NeoplasmMalignant NeoplasmsMalignant neoplasm of ovaryMammalian OviductsMeasuresMediatingModelingMorbidity - disease rateMusMutationNeoplasm MetastasisNormal tissue morphologyNuclearNude MiceOncogenesOncogenicOncoproteinsOrphanPathway interactionsPharmaceutical PreparationsPlayProliferatingProteinsRAD9A geneRecurrenceRecurrent diseaseReportingResistanceRoleSerousSignal TransductionSiteTestingThe Cancer Genome AtlasTherapeuticTherapeutic IndexTimeUnited StatesWestern BlottingX-Ray CrystallographyXenograft procedureadvanced diseasebiological adaptation to stresscancer cellcancer therapychemotherapycounterscreenhigh standardhigh throughput screeninghomologous recombinationin vivoinhibitorinnovationintraperitonealknockout genemortalitynew therapeutic targetnovelnovel therapeutic interventionnovel therapeuticsoverexpressionprotein complexprotein functionprotein protein interactionreplication stressresponsesmall moleculesmall molecule inhibitorsmall molecule librariestherapeutic developmenttherapeutic targettumortumor growth

项目摘要

项目成果

ADAM R. KARPF的其他基金

相似基金

相关文献

中文摘要
翻译
项目摘要 高级别浆液性卵巢癌(HGSC)是卵巢癌中最常见和最致命的亚型。 HGSC中的致癌驱动因子和治疗靶标是DNA复制应激(RS)。蜂窝RS响应 包括作为治疗靶点研究的几种蛋白质。的致癌作用的表征 在RS反应中起作用的蛋白质及其作为治疗靶点的发展将影响HGSC 治疗方法。在这种情况下,RAD 9,RAD 1和HUS 1相互作用的核孤儿(RHNO 1)起着重要的作用。 在HGSC RS反应中的重要作用。RHNO 1与RAD 9-RAD 1-HUS 1复合物(9-1-1)相互作用, 促进ATR-CHK 1信号传导、同源重组(HR)DNA修复、细胞存活和化疗 阻力RHNO 1通常在HGSC中过表达,包括在复发性化疗耐药疾病中。 在正常输卵管上皮(FTE)细胞中的RHNO 1敲除(KO)不会损害细胞活力,这表明 靶向RHNO 1功能的药物将具有高治疗指数。在这里,我们将探讨的作用, RHNO 1在体内HGSC中的作用,并将鉴定RHNO 1与9-1-1复合物相互作用的一流抑制剂。 我们的总体目标是为HGSC开发一种新的治疗方法。 具体目标1。使用原位异种移植确定RHNO 1在体内HGSC中的作用。 原位异种移植是一种在人体肿瘤中测定癌基因功能的体内方法。 我们将在两种人类HGSC细胞系OVCAR 4和OVCAR 8中使用CRISPR KO消融RHNO 1,该模型 转移性、复发性疾病。我们将经腹膜内(IP)将标记有谷胱甘肽转移酶的细胞植入无胸腺细胞中, 裸鼠,因为腹膜腔是模拟晚期和复发性HGSC最相关的原位部位 用于治疗发展。在子目标1A中,我们将使用成像测量肿瘤生长动力学,以及 小鼠存活、转移生长和腹水。在子目标1B中,我们将测量增殖的生物标志物, RS反应、DNA损伤和细胞凋亡。在子目标1C中,我们将确定RHNO 1 KO的灵敏度, 卡铂或奥拉帕尼化学疗法的对照异种移植物,对于 HGSC。 具体目标2。开发一流的破坏RHNO 1/9-1-1相互作用的化合物。那里 没有RHNO 1功能的小分子抑制剂(SMI)。在这里,我们将开发经过验证的RHNO 1模拟物, 破坏RHNO 1/9-1-1相互作用和HGSC细胞中的RS反应,预期其抑制HGSC细胞 生存在子目标2A中,我们将使用100,000个 化合物内部化学库和新开发的9-1-1/RHNO 1荧光偏振(FP)测定。 在子目标2B中,我们将使用可用的基于FP的计数器屏幕测试识别的命中。在子目标2C中,我们 将与9-1-1复合的命中物进行X射线晶体学分析,这将为未来的药物设计参数提供信息。 在Sub-Aim 2D中,我们将测试命中化合物在HGSC细胞中的靶向接合。
英文摘要
Project Summary High-grade serous ovarian cancer (HGSC) is the most common and deadly subtype of ovarian cancer. An oncogenic driver and therapeutic target in HGSC is DNA replication stress (RS). The cellular RS response includes several proteins under investigation as therapeutic targets. Characterization of the oncogenic role of proteins that function in the RS response, and their development as therapeutic targets, will impact HGSC treatment approaches. In this context, RAD9, RAD1, and HUS1 Interacting Nuclear Orphan (RHNO1) plays an important role in the HGSC RS response. RHNO1 interacts with the RAD9-RAD1-HUS1 complex (9-1-1) to promote ATR-CHK1 signaling, homologous recombination (HR) DNA repair, cell survival, and chemotherapy resistance. RHNO1 is commonly overexpressed in HGSC, including in recurrent chemoresistant disease. RHNO1 knockout (KO) in normal fallopian tube epithelial (FTE) cells does not impair cell viability, suggesting that drugs targeting RHNO1 function will have a high therapeutic index. Here, we will investigate the role of RHNO1 in HGSC in vivo and will identify first-in-class inhibitors of the RHNO1 interaction with the 9-1-1 complex. Our overarching goal is to develop a new therapeutic approach for HGSC. Specific Aim 1. Determine the role of RHNO1 in HGSC in vivo using orthotopic xenografting. Orthotopic xenografting is an in vivo approach to determine oncogene function in the context of a human tumor. We will ablate RHNO1 using CRISPR KO in two human HGSC cells lines, OVCAR4 and OVCAR8, that model metastatic, recurrent disease in vivo. We will implant luciferase-tagged cells intraperitoneally (IP) into athymic nude mice, as the peritoneal cavity is the orthotopic site that mimics late stage and recurrent HGSC most relevant for therapeutic development. In Sub-Aim 1A, we will measure tumor growth kinetics using imaging, as well as mouse survival, metastatic growth, and ascites. In Sub-Aim 1B, we will measure biomarkers of proliferation, the RS response, DNA damage, and apoptosis. In Sub-Aim 1C, we will determine the sensitivity of RHNO1 KO and control xenografts to carboplatin or olaparib chemotherapy, agents which have high therapeutic relevance for HGSC. Specific Aim 2. Develop first-in-class compounds that disrupt the RHNO1/9-1-1 interaction. There are no small molecule inhibitors (SMI) of RHNO1 function. Here, we will develop validated RHNO1 mimics that disrupt the RHNO1/9-1-1 interaction and the RS response in HGSC cells, which is expected to inhibit HGSC cell survival. In Sub-Aim 2A, we will conduct a high-throughput screening (HTS) campaign using a 100,000 compound in-house chemical library and a newly developed 9-1-1/RHNO1 fluorescence polarization (FP) assay. In Sub-Aim 2B, we will test the identified hits using an available FP-based counter screen. In Sub-Aim 2C, we will subject hits in complex with 9-1-1 to X-ray crystallography, which will inform future drug design parameters. In Sub-Aim 2D, we will test hit compounds for target engagement in HGSC cells.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Epigenetic regulation of cancer/germ-line antigen gene expression
Green tea-mediated inhibition of aberrant DNA hypermethylation in prostate cancer
Epigenetic regulation of cancer/germ-line antigen gene expression
Epigenetic regulation of cancer/germ-line antigen gene expression
海外基金